VNDA earnings date and last-quarter result: next report 2026-07-30, last quarter miss, P/E -1.32. Updated 2026-07-23.
Vanda Pharmaceuticals (VNDA) Research Hub
Vanda Pharmaceuticals (VNDA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 3.94 USD (-1.75%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.32, market cap 0.33B. This hub links to the full technical, earnings and options research available for VNDA.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.94 USD (-1.75%) |
| 52-week range | 3.875 USD – 6.6 USD |
| Trend regime | Range |
| 14-day RSI | 24.6 (Oversold) |
| Trailing P/E | -1.32 |
| Market cap | 0.33B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for VNDA
Covered Call on VNDA: how it works, illustrative setup around the real 3.94 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on VNDA: how it works, illustrative setup around the real 3.94 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on VNDA: how it works, illustrative setup around the real 3.94 USD price, max profit/loss, breakeven and when to use it. Educational.
VNDA technical analysis: range, last 3.94 USD, RSI 24.6, 52w range 3.875 USD–6.6 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is VNDA in?
Vanda Pharmaceuticals (VNDA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is VNDA in an uptrend or downtrend?
As of 2026-10-26, VNDA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is VNDA's trailing P/E ratio?
VNDA's trailing P/E is -1.32, with a market cap of 0.33B. See the earnings research page for full valuation detail.
When does VNDA next report earnings?
VNDA is next scheduled to report earnings on 2026-07-30.